P2E
(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]hept-5-enoic acid
Created: | 2009-06-04 |
Last modified: | 2021-03-01 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 57 |
Chiral Atom Count | 4 |
Bond Count | 57 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]hept-5-enoic acid |
Synonyms | Prostaglandin E2 |
Systematic Name (OpenEye OEToolkits) | (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]hept-5-enoic acid |
Formula | C20 H32 O5 |
Molecular Weight | 352.465 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C1CC(O)C(/C=C/C(O)CCCCC)C1C\C=C/CCCC(=O)O |
SMILES | CACTVS | 3.341 | CCCCC[CH](O)C=C[CH]1[CH](O)CC(=O)[CH]1CC=CCCCC(O)=O |
SMILES | OpenEye OEToolkits | 1.5.0 | CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O |
Canonical SMILES | CACTVS | 3.341 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | CCCCC[C@@H](\C=C\[C@H]1[C@@H](CC(=O)[C@@H]1C\C=C/CCCC(=O)O)O)O |
InChI | InChI | 1.03 | InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1 |
InChIKey | InChI | 1.03 | XEYBRNLFEZDVAW-ARSRFYASSA-N |
Drug Info: DrugBank
DrugBank ID | DB00917 |
---|---|
Name | Dinoprostone |
Groups | approved |
Description | Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour. |
Synonyms |
|
Brand Names |
|
Indication | For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage. |
Categories |
|
ATC-Code | G02AD02 |
CAS number | 363-24-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Prostaglandin E2 receptor EP2 subtype | MGNASNDSQSEDCETRQWLPPGESPAISSVMFSAGVLGNLIALALLARRW... | unknown | agonist |
Prostaglandin E2 receptor EP1 subtype | MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSN... | unknown | agonist |
Prostaglandin E2 receptor EP3 subtype | MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSV... | unknown | agonist |
Prostaglandin E2 receptor EP4 subtype | MSTPGVNSSASLSPDRLNSPVTIPAVMFIFGVVGNLVAIVVLCKSRKEQK... | unknown | agonist |
Prostaglandin D2 receptor 2 | MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVEN... | unknown | agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL548 |
PubChem | 5280360 |
ChEMBL | CHEMBL548 |
ChEBI | CHEBI:15551 |